Delivery Order SPE2DB25D3504-SPE2DB25FVWAX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $10,167.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 11, 2025, with completion targeted for August 12, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,827.73 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 19, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $44,409.63 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on July 30, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents a single transaction with a completion date of July 31, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,403.76 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 14, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB25FVWAXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,706.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 20, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by August 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical systems, particularly supporting military and veteran healthcare procurement needs through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Zepbound, a GLP-1 receptor agonist medication, represents the type of specialty pharmaceutical commodity covered under this expansive contract vehicle, which encompasses brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 8/20/25 |